Article
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.
The Journal of experimental medicine - 9 Apr 2012
Azoitei Ninel, Hoffmann Christopher M, Ellegast Jana M, Ball Claudia R, Obermayer Kerstin, Gößele Ulrike, Koch Britta, Faber Katrin, Genze Felicitas, Schrader Mark, Kestler Hans A, Döhner Hartmut, Chiosis Gabriela, Glimm Hanno, Fröhling Stefan, Scholl Claudia
Abstract excerpt
Previous efforts to develop drugs that directly inhibit the activity of mutant KRAS, the most commonly mutated human oncogene, have not been successful. Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33 as a context-dependent therapeutic target. However, specific strategies for interfering with the critical functions...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.